Compare SABR & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | LXRX |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 735.3M | 703.3M |
| IPO Year | 2014 | 2000 |
| Metric | SABR | LXRX |
|---|---|---|
| Price | $2.09 | $2.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $4.15 |
| AVG Volume (30 Days) | ★ 5.7M | 4.1M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 77.78 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $3,866,956,000.00 | $49,803,000.00 |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $104.50 | ★ N/A |
| Revenue Growth | 7.46 | ★ 60.24 |
| 52 Week Low | $0.81 | $1.00 |
| 52 Week High | $3.30 | $2.68 |
| Indicator | SABR | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 57.91 |
| Support Level | $1.51 | $1.17 |
| Resistance Level | $2.24 | $2.53 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 79.82 | 55.00 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.